IVESTATIN THERAPEUTICS develops new products to provide breakthrough solutions to reduce ischemic damage.
Acute Coronary Syndrome (ACS) is the single most common cause of death, and its frequency is increasing.
• An estimated 17.9 million people died from ACS in 2016, representing 31% of all global deaths.
• Current costs for ACS are $89 billion (projected to $215 billion in 2035).
• Global DALYs related to ACS for all ages increased 29,2% between 1990 (100,473 thousands) and 2010 (129,820 thousands).